TUMOR NECROSIS FACTOR-ALPHA

Clinical trials for TUMOR NECROSIS FACTOR-ALPHA explained in plain language.

Never miss a new study

Get alerted when new TUMOR NECROSIS FACTOR-ALPHA trials appear

Sign up with your email to follow new studies for TUMOR NECROSIS FACTOR-ALPHA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Could an arthritis drug shrink dangerous brain aneurysms?

Disease control Recruiting now

This study tests whether infliximab (Remicade), a drug used for arthritis and other inflammatory conditions, can shrink a specific type of brain aneurysm called a dolichoectactic vertebrobasilar (DVB) aneurysm. These aneurysms are difficult to treat with surgery or stents, and th…

Matched conditions: TUMOR NECROSIS FACTOR-ALPHA

Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control

Last updated Jun 27, 2026 13:06 UTC

TUMOR NECROSIS FACTOR-ALPHA

Get alerted when new TUMOR NECROSIS FACTOR-ALPHA trials appear

Could an arthritis drug shrink dangerous brain aneurysms?